Sun Pharmaceutical Industries share price
NSE: SUNPHARMABSE: 524715Pharmaceuticals & BiotechnologyLarge Cap
Sun Pharmaceutical Industries Limited · Formerly Sun Pharmaceuticals Industries · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1994 on BSE, Feb 1995 on NSE
Last close ₹1,751.20up ₹11.20 (0.64%)BSE ₹1,760.00
Share price at the NSE close on 27 Oct 2026. Previous close ₹1,740.00.
27 Oct: open ₹1,740.00, high ₹1,767.90, low ₹1,740.00
52-week range of traded prices to 27 Oct 2026
₹1,583.70Low, 29 Jan 2026₹2,046.90High, 31 Jul 2026
- Next results date: the board meets on 30 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,20,172 Cr13th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 34.74
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.03
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.91%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.05
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 15,47,89863.5% delivered
About Sun Pharmaceutical Industries
Sun Pharmaceutical Industries Limited is a drug maker based in India that makes and sells specialty medicines, branded and unbranded generic medicines, consumer health products and active pharmaceutical ingredients (APIs, the drug substance inside a medicine).1 It sells in India, the United States, emerging markets such as Romania, Russia, South Africa, Brazil and Mexico, and other developed markets including Western Europe, Canada and Japan.234
It operates in more than 100 countries and has more than 47,000 employees.56 The business is organised into the US, India, emerging markets, the rest of the world and APIs; specialty medicine sales are also disclosed as a whole, and consumer health sales are reported within the markets.7 Its consumer health brands include Revital and Volini, and it sells consumer health products in more than 25 countries.89 The API business makes about 400 APIs, for its own medicines and for other generic and patent-holding drug makers.1011
The business began in 1983 with 5 products; the company was incorporated in 1993 and raised ₹550 million in its first public share sale in 1994.1213 It acquired Taro Pharma of Israel in 2010 and took full ownership in 2024, and merged with Ranbaxy in 2015.14 In 2025 it acquired Checkpoint Therapeutics, an immunotherapy and cancer drug company.1516
Dilip Shanghvi is Executive Chairman, and Kirti Ganorkar took over as Managing Director during the year to Mar 2026.17 Its registered office is in Vadodara, Gujarat, and its corporate office in Mumbai.18
Sun Pharmaceutical Industries key points
Results
- In the quarter to Jun 2026, consolidated sales rose 10.1% on a year earlier and EBITDA (profit before interest, tax, depreciation and amortisation) rose 2.7% to ₹44,177 million.1920
- Reported net profit for the quarter was ₹28,948 million, against ₹22,786 million a year earlier; the company adjusts out one-off items of ₹1,946 million from the latest quarter and ₹7,175 million from the year-earlier one.2021
- In the year to Mar 2026, consolidated gross sales rose 11.9% to ₹582 billion, EBITDA rose 16.1% to ₹177 billion and reported net profit rose 5.0% to ₹115 billion; adjusted net profit was ₹124 billion.2223
Market position
- The company ranks first in the Indian pharmaceutical market, with an 8.5% share in the year to Jun 2026, against 8.2% in the previous period.24
- In India it ranks first by prescriptions among 12 categories of doctors, and its sales volume grew 5.4% in the quarter to Jun 2026, against 2% for the market.25
- In the US it is the 13th largest seller of generic medicines over the 12 months to Jun 2026, and ranks 2nd by prescriptions in dermatology over the 12 months to Jul 2026.26
Business segments
- Share of consolidated sales by business (formulations are finished medicines)27
Item year to Mar 2026 India formulations 33% US formulations 29% Emerging markets formulations 19% Rest of world formulations 15% APIs and others 4% - Specialty medicines in dermatology, ophthalmology and onco-dermatology (skin cancers) made up 22% of consolidated sales in the year to Mar 2026, from 29 products marketed worldwide; in the US they outsold the company's generics for the first time.282930
- In the quarter to Jun 2026, specialty medicine sales rose 12.8% to 21.9% of consolidated sales, while US sales fell 9.7% as generic sales dropped, largely on lenalidomide erosion.3132
- ILUMYA, for plaque psoriasis (a chronic skin disease), is the largest specialty product, with $796 million of sales in the year to Mar 2026; LEQSELVI, for severe alopecia areata (hair loss), and UNLOXCYT, for an advanced skin cancer, launched in the US that year.333435
Plants and capacity
Research and development
- In the year to Mar 2026, R&D spending was ₹35,540 million, 6.1% of sales; the company has more than 2,700 R&D staff and 6 R&D centres worldwide.3839
- As of June 2026 it had filed 677 ANDAs (applications to sell a generic medicine in the US) and 70 NDAs (applications to approve a new drug); 558 and 57 were approved, and 119 ANDAs and 13 NDAs awaited approval.40
What the company expects
- The company said on its earnings call for the quarter to Jun 2026 that it expects revenue growth in the high single digits for the year to Mar 2027.4142
- The company said on the same call that it expects to complete its acquisition of Organon & Co. in the quarter to Mar 2027.43
- In its exchange filing of 27 Apr 2026, the company said after the Organon deal it expects to rank among the top 25 global drug makers, with combined revenue of $12.4 billion on both companies' past annual results and specialty medicines at 27% of revenue.44
Recent events
- On 13 Oct 2026, CRISIL and ICRA rated the company's proposed non-convertible debentures (bonds that cannot be turned into shares) AAA with a stable outlook, and reaffirmed their ratings on its existing facilities.45
- On 28 Sep 2026, the company licensed lerodalcibep, a once-monthly injection that lowers LDL (bad) cholesterol, approved in the EU as Lyrokaul, from LIB Therapeutics, with rights to make and sell it worldwide except the US and China.46
- On 24 Jul 2026, Organon's shareholders approved its acquisition by Sun Pharma; the deal remained subject to other closing conditions, including regulatory approvals.47
- On 27 Apr 2026, the company agreed to buy Organon & Co., which sells over 70 women's health and general medicines, including biosimilars (copies of biologic drugs), in 140 countries, for $14.00 a share in cash, valuing it at $11.75 billion including debt.48
Litigation and regulatory matters
- On 17 Aug 2026, the company said a US appeals court had upheld summary judgment (a ruling without trial) for it in antitrust suits over a 2008 settlement with Pfizer on generic Lipitor, substantially ending the case subject to any further remedies.49
- The US drug regulator classified the Halol plant in Gujarat as Official Action Indicated (compliance improvements needed) in September 2025, and the Baska plant in December 2025; as of the annual report of 6 Jul 2026, the company was working to restore full compliance.50
Last updated
All 50 sources, each with its page
- 1. Annual report, 6 Jul 2026, page 6
- 2. Investor presentation, 22 Sep 2026, page 5
- 3. Investor presentation, 22 Sep 2026, page 33
- 4. Investor presentation, 22 Sep 2026, page 6
- 5. Annual report, 6 Jul 2026, page 5
- 6. Annual report, 6 Jul 2026, page 12
- 7. Annual report, 6 Jul 2026, page 34
- 8. Annual report, 6 Jul 2026, page 44
- 9. Annual report, 6 Jul 2026, page 6
- 10. Annual report, 6 Jul 2026, page 44
- 11. Annual report, 6 Jul 2026, page 45
- 12. Investor presentation, 22 Sep 2026, page 56
- 13. Annual report, 6 Jul 2026, page 108
- 14. Annual report, 6 Jul 2026, page 31
- 15. Annual report, 6 Jul 2026, page 31
- 16. Investor presentation, 22 Sep 2026, page 23
- 17. Annual report, 6 Jul 2026, page 12
- 18. Annual report, 6 Jul 2026, page 344
- 19. Earnings call, 31 Jul 2026, page 3
- 20. Earnings call, 31 Jul 2026, page 4
- 21. Investor presentation, 22 Sep 2026, page 53
- 22. Annual report, 6 Jul 2026, page 36
- 23. Annual report, 6 Jul 2026, page 14
- 24. Earnings call, 31 Jul 2026, page 5
- 25. Earnings call, 31 Jul 2026, page 5
- 26. Investor presentation, 22 Sep 2026, page 22
- 27. Investor presentation, 22 Sep 2026, page 6
- 28. Annual report, 6 Jul 2026, page 10
- 29. Annual report, 6 Jul 2026, page 32
- 30. Annual report, 6 Jul 2026, page 14
- 31. Earnings call, 31 Jul 2026, page 4
- 32. Earnings call, 31 Jul 2026, page 5
- 33. Investor presentation, 22 Sep 2026, page 20
- 34. Annual report, 6 Jul 2026, page 40
- 35. Annual report, 6 Jul 2026, page 14
- 36. Investor presentation, 22 Sep 2026, page 45
- 37. Annual report, 6 Jul 2026, page 46
- 38. Annual report, 6 Jul 2026, page 45
- 39. Annual report, 6 Jul 2026, page 6
- 40. Investor presentation, 22 Sep 2026, page 22
- 41. Earnings call, 31 Jul 2026, page 10
- 42. Earnings call, 31 Jul 2026, page 19
- 43. Earnings call, 31 Jul 2026, page 6
- 44. Exchange filing, 27 Apr 2026, page 2
- 45. Exchange filing, 13 Oct 2026, page 1
- 46. Exchange filing, 28 Sep 2026, page 2
- 47. Exchange filing, 24 Jul 2026, page 2
- 48. Exchange filing, 27 Apr 2026, page 2
- 49. Exchange filing, 17 Aug 2026, page 1
- 50. Annual report, 6 Jul 2026, page 144
Results
Consolidated; ₹ crore.Sun Pharmaceutical Industries quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +11.4%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +16.6%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹15,300 Crup 4.71%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹2,901 Crup 7.07%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 19.0%
Revenue by quarter
Peak revenue ₹15,521 Cr, quarter to Dec 2025; lowest ₹12,959 Cr, quarter to Mar 2025
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13,291 | 13,675 | 12,959 | 13,851 | 14,478 | 15,521 | 14,612 | 15,300 |
| Net profit | 3,037 | 2,913 | 2,154 | 2,293 | 3,125 | 3,381 | 2,710 | 2,901 |
| Net margin | 22.9% | 21.3% | 16.6% | 16.6% | 21.6% | 21.8% | 18.5% | 19.0% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹58,462 Crup 11.19%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹11,509 Crup 4.96%
- Net margin
- 19.7%
Revenue by year
Peak revenue ₹58,462 Cr, year to Mar 2026; lowest ₹26,489 Cr, year to Mar 2018
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31,578 | 26,489 | 29,066 | 32,838 | 33,498 | 38,654 | 43,886 | 48,497 | 52,578 | 58,462 |
| Net profit | 7,846 | 2,608 | 3,208 | 4,172 | 2,272 | 3,389 | 8,513 | 9,610 | 10,965 | 11,509 |
| Net margin | 24.8% | 9.8% | 11.0% | 12.7% | 6.8% | 8.8% | 19.4% | 19.8% | 20.9% | 19.7% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history.Sun Pharmaceutical Industries PE ratio and valuation
Price to earnings
At or below today's level on 74% of 2,217 trading days since Nov 2016.
LowestHighest
Its median28.54Industry median28.32
Price to book
At or below today's level on 65% of 1,971 trading days since Nov 2018.
LowestHighest
Its median4.44Industry median2.96
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 59% of 2,472 trading days over the last 10 years.
LowestHighest
Its median0.85%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +2.2% | +4.8% | −3.4% | 0.9% |
| 3 years | +22.2% | +10.6% | +9.7% | 0.9% |
| 5 years | +25.1% | +31.6% | −5.7% | 1.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the years to Mar 2021 and Mar 2026.
Mutual fund holdings
517 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 203 of the 277 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 7 more funds filed their first portfolio on record, holding it.All 517 funds holding Sun Pharmaceutical Industries
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 3
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 4
- AddedAdded. Funds that held more shares than at the end of the month before.
- 154
- CutCut. Funds that held fewer shares than at the end of the month before.
- 123
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 226
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 7
| Fund | |||
|---|---|---|---|
 SBI Nifty 50 ETFSBI Mutual Fund | 2,05,37,460 | 1.84% | ₹3,730.8 Cr |
| SBI BSE Sensex ETFSBI Mutual Fund | 1,45,07,940 | 2.28% | ₹2,640.4 Cr |
 ICICI Prudential Value FundICICI Prudential Mutual Fund | 1,37,69,894 | 4.37% | ₹2,501.4 Cr |
| ICICI Prudential Aggressive Hybrid FundICICI Prudential Mutual Fund | 98,53,039 | 3.53% | ₹1,789.9 Cr |
 HDFC Balanced Advantage FundHDFC Mutual Fund | 87,46,339 | 1.55% | ₹1,588.9 Cr |
| ICICI Prudential Large Cap FundICICI Prudential Mutual Fund | 87,39,509 | 2.08% | ₹1,587.6 Cr |
| SBI Aggressive Hybrid FundSBI Mutual Fund | 79,00,000 | 1.67% | ₹1,435.1 Cr |
 UTI Nifty 50 ETFUTI Mutual Fund | 70,43,274 | 1.84% | ₹1,279.5 Cr |
| UTI BSE Sensex ETFUTI Mutual Fund | 68,36,189 | 2.28% | ₹1,244.2 Cr |
 Nippon India ETF Nifty 50 BeESNippon India Mutual Fund | 65,93,147 | 1.84% | ₹1,197.7 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Sun Pharmaceutical Industries insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 23 pledge filings of unclear kind
- Others: no market trade · 1 pledge filing of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Sun Pharmaceutical Industries competitors and peers
Pharmaceuticals, 215 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Sun Pharmaceutical Industries in market cap. 1 company in its own group left out: one owns more than half of the other, directly or through a company it controls, or one owner more than half of both.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Divi's LaboratoriesDIVISLAB | 2,52,341 | 86.27 | 15.06 | +16.3% | +26.8% | 18.4% | 20.8% | 0.32% |
 Torrent PharmaceuticalsTORNTPHARM | 1,75,920 | 82.82 | 9.57 | +42.1% | −0.7% | 15.8% | 12.0% | 0.82% |
 Zydus LifesciencesZYDUSLIFE | 1,16,997 | 25.92 | 4.32 | +21.1% | −1.3% | 17.7% | 15.9% | 0.09% |
 Laurus LabsLAURUSLABS | 1,15,735 | 105.85 | 21.84 | +22.6% | +114.9% | 22.4% | 19.8% | 0.09% |
 Dr. Reddy's LaboratoriesDRREDDY | 1,09,343 | 39.05 | 2.82 | −3.5% | −51.5% | 7.5% | 6.0% | 0.61% |
 CiplaCIPLA | 1,09,063 | 37.65 | 3.08 | −0.7% | −46.8% | 8.5% | 9.7% | 0.96% |
 Mankind PharmaMANKIND | 1,03,365 | 45.97 | 5.88 | +13.3% | +28.4% | 13.7% | 13.6% | 0.00% |
 Aurobindo PharmaAUROPHARMA | 93,643 | 25.22 | 2.47 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Sun Pharmaceutical Industries dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹16.00 a share, years to Mar 2025 and Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 7 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹5.00 |
| 5 Feb 2026 | Interim | ₹11.00 |
| 7 Jul 2025 | Final | ₹5.50 |
| 6 Feb 2025 | Interim | ₹10.50 |
| 12 Jul 2024 | Final | ₹5.00 |
| 9 Feb 2024 | Interim | ₹8.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Sun Pharmaceutical Industries announcements
Oct 2026
23 Oct · Business
20 Oct · Business
15 Oct · Analysts
13 Oct · Rating
Sun Pharmaceutical Industries annual report, year to Mar 2026
Sun Pharmaceutical Industries share price by year
Each calendar year to 2025.Sun Pharmaceutical Industries share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,719.70 | −8.8% | 1,889.95 | 1,563.30 |
| 2024 | 1,886.35 | +49.8% | 1,948.70 | 1,260.25 |
| 2023 | 1,259.45 | +25.8% | 1,262.15 | 925.85 |
| 2022 | 1,001.40 | +18.4% | 1,051.95 | 793.40 |
| 2021 | 845.70 | +42.8% | 845.70 | 564.35 |
| 2020 | 592.35 | +36.9% | 592.35 | 324.50 |
| 2019 | 432.55 | +0.5% | 478.85 | 366.80 |
| 2018 | 430.50 | −24.6% | 677.40 | 399.00 |
| 2017 | 571.15 | −9.3% | 710.80 | 450.00 |
| 2016 | 630.00 | −23.2% | 882.45 | 609.15 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 26 Oct 2026 | 1,752.40 | 1,766.00 | 1,729.40 | 1,740.00 | 1,745.78 | 16,22,698 | 59.1% |
| 23 Oct 2026 | 1,757.40 | 1,765.40 | 1,735.20 | 1,748.00 | 1,745.90 | 10,64,528 | 60.0% |
| 22 Oct 2026 | 1,732.00 | 1,758.00 | 1,719.10 | 1,758.00 | 1,745.38 | 17,78,519 | 65.9% |
| 21 Oct 2026 | 1,753.00 | 1,755.60 | 1,721.10 | 1,745.10 | 1,734.43 | 23,16,342 | 66.2% |
| 19 Oct 2026 | 1,758.80 | 1,768.90 | 1,735.30 | 1,743.00 | 1,747.00 | 8,29,445 | 53.9% |
| 16 Oct 2026 | 1,762.20 | 1,764.90 | 1,743.50 | 1,758.80 | 1,754.83 | 15,22,459 | 62.6% |
| 15 Oct 2026 | 1,736.00 | 1,778.00 | 1,734.10 | 1,764.00 | 1,765.35 | 13,76,380 | 65.9% |
| 14 Oct 2026 | 1,770.10 | 1,770.10 | 1,725.50 | 1,746.40 | 1,739.85 | 18,08,782 | 68.3% |
| 13 Oct 2026 | 1,760.00 | 1,770.70 | 1,750.60 | 1,770.70 | 1,762.86 | 11,91,057 | 61.1% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus shares and stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 29 Jul 2013 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 25 Nov 2010 | Split | 0.2000 | Each share became 5. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- SUNPHARMA
- BSE code
- 524715
- ISIN
- INE044A01036
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.sunpharma.com
- CIN
- L24230GJ1993PLC019050
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1993
- Registered office
- SPARC, Tandalja, Vadodara 390012, Gujarat
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 50, BSE Sensex, Nifty 100, BSE 100, Nifty 200, BSE 200